Archives

  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01

    • Aztreonam: Synthetic β-Lactam Antibiotic for Gram-Negativ...

    2026-03-31

    Aztreonam: Synthetic β-Lactam Antibiotic for Gram-Negative Research

    Principle Overview: Mechanism and Research Significance

    Aztreonam is a first-in-class, totally synthetic monocyclic β-lactam antibiotic tailored to target Gram-negative aerobic bacteria. Its mechanism of action is rooted in the inhibition of bacterial cell wall synthesis—specifically, Aztreonam binds to penicillin-binding proteins, leading to rapid cell lysis and death of susceptible pathogens. This precise specificity for Gram-negative species distinguishes it from other β-lactam antibiotics, making it invaluable in antibiotic activity research and multidrug-resistant (MDR) infection models. The chemical structure (C13H17N5O8S2, MW 435.43) confers stability and high aqueous solubility, facilitating its use across diverse experimental systems.

    Recent epidemiological studies, such as the comprehensive investigation by Chen et al. (2025), underscore the urgency of research on carbapenem-resistant Enterobacter cloacae (CREC) in clinical settings. Aztreonam's unique mode of action and resistance profile make it an essential tool for probing these challenging pathogens and for advancing drug metabolism and cytochrome P450 modulation research.

    Experimental Workflow: From Compound Preparation to Assay Readout

    Step 1: Compound Handling and Preparation

    • Storage: Aztreonam is supplied as a solid (e.g., Aztreonam 100mg solid) and should be stored at -20°C for optimal stability. Short-term exposure to ambient temperatures is permissible during setup, but solutions should be freshly prepared for each experiment.
    • Solubility: The compound exhibits excellent solubility in water (≥10.24 mg/mL, especially with ultrasonic assistance) and in DMSO (≥18.9 mg/mL). For most in vitro assays, a working stock of Aztreonam 10mM in DMSO or in sterile water is recommended. Avoid ethanol, as Aztreonam is insoluble in this solvent.
    • Preparation Protocol:
      1. Weigh the required amount of Aztreonam (e.g., for a 10mM solution, dissolve 4.35 mg in 1 mL DMSO).
      2. Vortex or sonicate briefly to ensure complete dissolution.
      3. Filter-sterilize using a 0.22 μm syringe filter when sterility is needed (e.g., for cell culture or microbiology assays).
      4. Aliquot and store Aztreonam solutions at -20°C for up to one week, minimizing freeze-thaw cycles.

    Step 2: Experimental Application in Gram-Negative Bacterial Assays

    • Broth Microdilution Assays: Aztreonam is a gold standard for evaluating antibiotic activity against Gram-negative aerobic bacteria. Prepare serial dilutions spanning the anticipated minimum inhibitory concentration (MIC) range (typically 0.25–256 μg/mL).
    • Resistance Phenotyping: Use Aztreonam to differentiate between β-lactamase-producing and non-producing isolates. Its stability to many β-lactamases makes it especially useful in carbapenem-resistant Enterobacter cloacae research, as highlighted in the Guangdong CREC study.
    • Colony Forming Unit (CFU) Assays: For bone marrow toxicity or progenitor cell inhibition research, supplement cell culture media with Aztreonam to model its impact on colony forming unit-erythroid (cfu-e), burst forming unit-erythroid (bfu-e), and colony forming units-granulocyte macrophage (cfu-gm) populations.

    Step 3: Mammalian Cell and Enzyme Modulation Studies

    • Cytochrome P450 Modulation: Aztreonam is a proven modulator of hepatic drug metabolism enzymes. In animal models (e.g., cynomolgus monkeys), intravenous administration (40–300 mg/kg/day for 4 weeks) significantly reduces liver microsomal cytochrome P450 content, particularly testosterone 6β-hydroxylase activity, without altering cytochrome b5 or NADPH-cytochrome c reductase activity.
    • Pharmacokinetic and Toxicology Studies: Use Aztreonam to probe antibiotic impact on hepatic enzymes and to model drug-drug interactions, especially when evaluating new antimicrobial combinations targeting MDR Gram-negative pathogens.

    Advanced Applications and Comparative Advantages

    Unraveling Resistance Mechanisms in Gram-Negative Pathogens

    With the global surge in antimicrobial resistance, particularly among Enterobacteriaceae, Aztreonam's role as a synthetic β-lactam antibiotic for Gram-negative bacteria is increasingly pivotal. Unlike carbapenems and cephalosporins, Aztreonam’s monocyclic β-lactam scaffold confers stability against many β-lactamases, except metallo-β-lactamases (e.g., blaNDM-1). This selectivity is exploited in MDR research, where Aztreonam is used to:

    • Dissect β-lactamase-mediated resistance phenotypes, especially in combination with β-lactamase inhibitors.
    • Complement phenotypic data with genotypic insights, such as the prevalence of blaNDM-1 and blaIMP in CREC (see Chen et al., 2025).
    • Enable high-throughput screens for novel antibiotic adjuvants.

    For a scenario-driven complement, the article "Aztreonam (SKU A5931): Optimizing Gram-Negative Bacterial..." details strategies for maximizing reproducibility and compatibility in Gram-negative bacterial studies. This resource extends the present protocol with practical guidance for workflow optimization in complex resistance settings.

    Bone Marrow Progenitor Cell Inhibition and Toxicology

    Aztreonam’s capacity to inhibit human bone marrow progenitor cells (cfu-e, bfu-e, cfu-gm) at clinically relevant concentrations supports its use in hematological toxicity models and colony forming unit assays. Quantitatively, significant inhibition is observed at both peak and trough serum concentrations, making it a benchmark compound for evaluating marrow toxicity risk in preclinical antibiotic discovery. For expanded mechanistic and translational perspectives, "Aztreonam in Multidrug Resistance Research: Mechanisms, M..." complements this article by linking molecular targets to advanced toxicology workflows.

    Cytochrome P450 Modulation: Implications for Drug Metabolism

    Beyond its antimicrobial spectrum, Aztreonam is a robust modulator of liver microsomal enzyme activity. The reduction in cytochrome P450 content—most notably testosterone 6β-hydroxylase—without affecting cytochrome b5 or NADPH-cytochrome c reductase, provides a unique model for pharmacokinetic interaction studies. This characteristic is critical for toxicology studies and for screening drug candidates for metabolic liabilities. In this context, "Aztreonam: Synthetic β-Lactam Antibiotic for Gram-Negativ..." offers an in-depth discussion connecting these findings to broader pharmacological research applications.

    Troubleshooting and Optimization Tips

    • Solubility Optimization: If encountering incomplete dissolution, apply brief sonication and use pre-warmed (37°C) DMSO or water. Avoid exceeding the recommended stock concentrations to prevent precipitation.
    • Compound Stability: Prepare fresh working solutions before each experiment and minimize light exposure. Discard any solution with visible turbidity or color change. Solid Aztreonam is stable at -20°C for >12 months when kept dry and protected from repeated temperature fluctuations.
    • Assay Controls: For MIC and CFU assays, include well-characterized Gram-negative reference strains (e.g., E. coli ATCC 25922) and known β-lactamase producers as positive/negative controls.
    • Cell Viability Assays: When modeling bone marrow toxicity, titrate Aztreonam concentrations and include untreated controls to define the dynamic range of progenitor cell inhibition.
    • Cytochrome P450 Studies: Standardize animal dosing regimens and employ validated analytical methods (e.g., LC-MS/MS or enzyme activity assays) to accurately quantify hepatic enzyme modulation.
    • Batch Consistency: Source Aztreonam from a trusted supplier like APExBIO to ensure lot-to-lot consistency and data reproducibility.

    Future Outlook: Empowering Next-Generation Antibiotic and Metabolism Research

    The rising tide of antimicrobial resistance, exemplified by the transmission dynamics of carbapenemase-encoding genes in Enterobacter cloacae (Chen et al., 2025), necessitates advanced research tools with defined specificity and mechanistic clarity. Aztreonam is uniquely positioned to meet these needs, serving as a foundation for antibiotic resistance studies, human colony forming unit assays, and hepatic enzyme modulation models.

    Looking forward, integration with high-throughput screening, genomic epidemiology, and combinatorial drug development will further enhance the value of Aztreonam in translational research. Its distinct solubility, stability, and pharmacological properties, as provided by APExBIO's Aztreonam, ensure robust performance across workflow scales and research domains.

    For continued protocol refinement, researchers are encouraged to consult complementary resources such as "Aztreonam: Mechanistic Innovation and Strategic Guidance ..." for expanded mechanistic and workflow insights.

    Conclusion

    In summary, Aztreonam’s role as a synthetic β-lactam antibiotic for Gram-negative bacteria is multifaceted—spanning antibiotic activity assays, bone marrow progenitor cell inhibition, and cytochrome P450 modulation. By following best practices in preparation, assay design, and troubleshooting, researchers can harness its full potential to address urgent questions in antibiotic resistance and pharmacological research. For reliable sourcing, performance validation, and technical support, APExBIO remains the trusted partner for Aztreonam research use only applications.